CN113875871A

CN113875871A - Health sugar

Info

Publication number: CN113875871A
Application number: CN202111183010.XA
Authority: CN
Inventors: 游全兵; 陈旭; 王羽娟; 石国良; 林卫军
Original assignee: Thomson Biotech Xiamen Pte Ltd
Current assignee: Gu Chuangxin Biotechnology Xiamen Co ltd
Priority date: 2021-10-11
Filing date: 2021-10-11
Publication date: 2022-01-04

Abstract

The invention relates to a healthy sugar. Specifically, the invention provides a composition which comprises arabinose and arabinoxylan. The arabinose and arabinoxylan according to the present invention have excellent synergistic effect in reducing blood sugar elevation caused by oral administration of saccharides, and provide a healthy sugar comprising arabinose, arabinoxylan and sucrose.

Description

Health sugar

Technical Field

The invention relates to the field of food, in particular to healthy sugar.

Background

As a favorite food, high-sugar diet prevails in various people, so that the incidence probability of diseases such as diabetes and the like related to hyperglycemia is increased, and the high-sugar diet causes harm to health. Moreover, with the continuous improvement of living standard, the processing of food (such as rice, wheat and the like) becomes increasingly refined, so that most of dietary fiber with higher content in the grain cortex is lost, the sugar content in the refined food is further improved, and the incidence rate of diseases related to hyperglycemia caused by high-sugar diet is further increased.

Although people know that the ingestion of sugar is reduced, high-sugar diet is avoided, and the whole grain is beneficial to health, people are hard to adapt to low-sugar and coarse grain diets due to the fact that people are used to a sweet pleased feeling caused by the high-sugar diet and a good taste caused by finely processed foods (such as white rice and white flour), so that the control of diseases related to hyperglycemia is not facilitated, and even for people related to hyperglycemia, such as diabetics, people with high blood sugar and obese people, the eating of high-sugar and finely processed foods (such as white rice and white flour) is difficult to resist, so that the disease prevention and control of people related to hyperglycemia, such as the diabetics, the people with high blood sugar and the obese people are not facilitated.

In the prior art, although the hypoglycemic substance and the sugar (such as sucrose) can be mixed to prepare the healthy sugar for reducing the blood sugar rise, the hypoglycemic substance and the sugar (such as sucrose) are easy to separate or layer during the daily transportation, taking and placing and the like due to the difference of physicochemical properties of the hypoglycemic substance and the sugar (such as sucrose), so that the content uniformity of the hypoglycemic substance and the sugar (such as sucrose) is reduced or does not meet the quality requirement, the content ratio of the hypoglycemic substance to the sugar in the whole using process of the healthy sugar can not be maintained, the stable blood sugar reducing effect of the hypoglycemic substance in the whole eating process of the healthy sugar can not be ensured, and the application value of the healthy sugar containing the hypoglycemic substance and the sugar (such as sucrose) is reduced.

In addition, the intestinal short-chain fatty acids such as acetic acid, propionic acid and butyric acid have beneficial effects on regulating the intestinal environment, are beneficial to maintaining the immune regulation and oxidation resistance of intestinal homeostasis, and are beneficial to reducing the occurrence probability of metabolic chronic diseases such as hyperglycemia, obesity and hyperlipidemia, and the like, so that the intestinal environment can be improved, the hyperglycemia can be reduced, and the health of the organism can be promoted by increasing the yield of the intestinal short-chain fatty acids such as acetic acid, propionic acid and butyric acid for people who are susceptible to diseases such as hyperglycemia, diabetes, obesity and the like.

Therefore, there is a need in the art to develop a method capable of reducing blood glucose, thereby preventing and treating hyperglycemia-related diseases.

Disclosure of Invention

The invention aims to provide arabinose and arabinoxylan which can reduce blood sugar, thereby preventing and treating diseases related to hyperglycemia.

In a first aspect, the present invention provides a composition comprising arabinose and arabinoxylan.

Preferably, the arabinose comprises L-arabinose.

Preferably, the weight ratio of arabinose to arabinoxylan is 1: 0.2-8, preferably 1: 1-5, more preferably 1: 1.5-3, more preferably 1: 1.5-2.5, more preferably 1: 1.8-2.2, more preferably 1: 2.

preferably, the composition is a pharmaceutical composition, a food composition or a health care composition.

Preferably, the composition further comprises a pharmaceutically, food or nutraceutical acceptable carrier.

Preferably, the composition is in a solid or liquid form.

Preferably, the composition is in the form of oral preparation or injection preparation.

Preferably, the composition is in the form of tablets, capsules, oral liquid, granules, powder or syrup.

In a second aspect the present invention provides the use of a composition according to the first aspect of the invention for the preparation of a medicament, food or dietary supplement for: (i) preventing and/or treating elevated blood glucose caused by oral administration of a saccharide; (ii) reducing the blood glucose rise caused by oral administration of carbohydrates; (iii) the content of short-chain fatty acid is increased; (iv) improving intestinal environment, promoting health of organism and/or preventing colorectal adenoma; and/or (v) facilitate the production of antibodies and enhance immunity.

Preferably, the carbohydrate comprises sucrose.

Preferably, the sugar substance comprises white granulated sugar.

Preferably, the short chain fatty acids include C1-C6 fatty acids.

Preferably, the short chain fatty acids comprise one or more of acetic acid, propionic acid and butyric acid.

Preferably, the short chain fatty acids comprise intestinal short chain fatty acids.

Preferably, the intestine comprises a small intestine and/or a large intestine.

Preferably, the term "increasing the content of short chain fatty acids" means increasing the content of short chain fatty acids in a subject.

Preferably, the subject comprises a human or non-human mammal.

Preferably, the subject is a human with a reduced content of short chain fatty acids.

Preferably, said "increasing the content of short chain fatty acids" means that the content of short chain fatty acids C1 is higher than C0 in said subject compared to the content of short chain fatty acids C0 in normal subjects; preferably, C1/C0 is greater than or equal to 1.1, preferably greater than or equal to 1.2, more preferably greater than or equal to 1.3, more preferably greater than or equal to 1.4, more preferably greater than or equal to 1.5, more preferably greater than or equal to 1.8, more preferably greater than or equal to 2, more preferably greater than or equal to 3, more preferably greater than or equal to 5, more preferably greater than or equal to 8.

Preferably, said "increasing the content of short chain fatty acids" means that the content of short chain fatty acids a1 is increased in the subject compared to the content of short chain fatty acids a0 at the time of or before administration of the composition to said subject.

Preferably, A1/A0 is ≥ 1.1, preferably ≥ 1.2, more preferably ≥ 1.3, more preferably ≥ 1.4, more preferably ≥ 1.5, more preferably ≥ 1.8, more preferably ≥ 2, more preferably ≥ 3, more preferably ≥ 5, more preferably ≥ 8.

In a third aspect, the invention provides a healthy sugar comprising arabinose, arabinoxylan and sucrose.

Preferably, the healthy sugar comprises a healthy sugar that lowers the Glycemic Index (GI).

Preferably, the arabinose comprises L-arabinose.

Preferably, the sucrose comprises white granulated sugar.

Preferably, said healthy sugar comprises a characteristic selected from the group consisting of:

(a) glycemic Index (GI) of less than or equal to 70, preferably 30-56, more preferably 40-54, more preferably 50-54, more preferably 51-53.

Preferably, the weight ratio of the arabinose, the arabinoxylan and the sucrose is (1-90): (1-50): (1-50).

preferably, the weight ratio of arabinose to sucrose is 1: 15-35, preferably 1: 20-30, more preferably 1: 22-27, more preferably 1: 25.

preferably, the weight ratio of said arabinoxylan to said sucrose is 1: 5-25, preferably 1: 5-20, more preferably 1: 10-15, more preferably 1: 12.5.

preferably, the weight ratio of the sucrose, the arabinose and the arabinoxylan is (45-55): (1-3): (3-5), preferably (47-53): (1.5-2.5): (3.5-4.5), more preferably (48-52): (1.8-2.2): (3.8-4.2).

Preferably, the weight ratio of the sucrose, the arabinose and the arabinoxylan is 0.5-99: 0.5-99: 0.5-99.

Preferably, the preparation of the healthy sugar is an oral preparation.

In a fourth aspect, the present invention provides a process for the preparation of a healthy sugar according to the third aspect of the present invention, said process comprising the steps of:

(1) crushing sucrose to obtain crushed sucrose, wherein the particle size distribution of the crushed sucrose is as follows: d10-85-92 μm, D50-140-265 μm, D90-245-265 μm;

(2) crushing arabinose to obtain crushed arabinose, wherein the particle size distribution of the crushed arabinose is as follows: d10 is 60-80 μm, D50 is 130 μm, D90 is 220 μm;

(3) pulverizing the arabinoxylan to obtain pulverized arabinoxylan, wherein the particle size distribution of the pulverized arabinoxylan is as follows: d10-35-55 μm, D50-70-90 μm, D90-120-140 μm;

(4) mixing the pulverized sucrose of step (1), the pulverized arabinose of step (2) and the pulverized arabinoxylan of step (3), said mixing comprising the steps of:

mixing 1/5 amount of pulverized sucrose, 1/4 amount of pulverized arabinose and 1/3 amount of pulverized arabinoxylan, adding 3/5 amount of pulverized sucrose, 2/4 amount of pulverized arabinose and 1/3 amount of pulverized arabinoxylan, mixing, and adding the rest 1/5 amount of pulverized sucrose, the rest 1/4 amount of pulverized arabinose and the rest 1/3 amount of pulverized arabinoxylan to obtain health sugar.

Preferably, in the step (1), the particle size distribution of the pulverized sucrose is as follows: d10-86-90 μm, D50-150-156 μm, and D90-253-260 μm.

Preferably, in the step (2), the particle size distribution of the crushed arabinose is as follows: d10-65-70 μm, D50-120-125 μm, and D90-210-215 μm.

Preferably, in the step (3), the particle size distribution of the pulverized arabinoxylan is as follows: d10-40-45 μm, D50-77-83 μm, and D90-130-135 μm.

Preferably, in the step (4), the mixing includes stirring and mixing in a mixing and stirring tank with stirring at the bottom center.

Preferably, in the step (4), the mixing includes the steps of:

stirring 1/5 amount of crushed sucrose, 1/4 amount of crushed arabinose and 1/3 amount of crushed arabinoxylan for 6-10min at the speed of 110-.

Preferably, in the step (4), the mixing includes the steps of:

stirring 1/5 amount of pulverized sucrose, 1/4 amount of pulverized arabinose and 1/3 amount of pulverized arabinoxylan for 7-9min at 125 revolutions/min under 115-minus one year, then adding 3/5 amount of pulverized sucrose, 2/4 amount of pulverized arabinose and 1/3 amount of pulverized arabinoxylan, stirring for 9-11min at 205-minus one year under 195-minus one year, and finally adding the rest 1/5 amount of pulverized sucrose, the rest 1/4 amount of pulverized arabinose and the rest 1/3 amount of pulverized arabinoxylan, stirring for 14-16min at 325-minus one year, thus obtaining the healthy sugar.

Preferably, the method produces healthy sugars with an inter-and intra-batch content uniformity RSD of < 2%.

It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments.

Detailed Description

The present invention has found that arabinose and arabinoxylan have an excellent synergistic effect in reducing the elevation of blood glucose caused by the oral administration of saccharides, and provides a healthy sugar comprising arabinose, arabinoxylan and sucrose.

Term(s) for

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

As used herein, the terms "comprising," "including," and "containing" are used interchangeably and include not only open-ended definitions, but also semi-closed and closed-ended definitions. In other words, the term includes "consisting of … …", "consisting essentially of … …".

As used herein, the glycemic index is abbreviated GI.

Composition comprising a metal oxide and a metal oxide

The invention provides a composition comprising arabinose and arabinoxylan.

In a preferred embodiment of the present invention, the arabinose comprises L-arabinose.

In a preferred embodiment of the present invention, the weight ratio of arabinose and arabinoxylan is 1: 0.2-8, preferably 1: 1-5, more preferably 1: 1.5-3, more preferably 1: 1.5-2.5, more preferably 1: 1.8-2.2, more preferably 1: 2.

in a preferred embodiment of the invention, the composition is a pharmaceutical composition, a food composition or a health-care product composition.

As used herein, the term "pharmaceutically, comestibly or nutraceutically acceptable carrier" refers to: one or more compatible solid, semi-solid, liquid or gel fillers suitable for human or animal use and of sufficient purity and sufficiently low toxicity.

It is to be understood that, in the present invention, the carrier is not particularly limited and may be selected from materials commonly used in the art, or prepared by a conventional method, or commercially available. Examples of the pharmaceutically acceptable carrier moiety are cellulose and its derivatives (e.g., methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, etc.), polyols (e.g., propylene glycol, glycerin, sorbitol, etc.), emulsifiers (e.g., tween), wetting agents (e.g., sodium laurylsulfate), buffers, chelating agents, thickeners, pH adjusters, transdermal enhancers, colorants, flavors, stabilizers, antioxidants, preservatives, bacteriostats, pyrogen-free water, etc.

In the present invention, the dosage form of the composition includes (but is not limited to) a solid preparation or a liquid preparation.

In the present invention, the dosage form of the composition includes (but is not limited to) oral preparation or injection preparation.

Use of

The present invention also provides the use of a composition according to the invention for the preparation of a medicament, food or dietary supplement for: (i) preventing and/or treating elevated blood glucose caused by oral administration of a saccharide; (ii) reducing the blood glucose rise caused by oral administration of carbohydrates; (iii) the content of short-chain fatty acid is increased; (iv) improving intestinal environment, promoting health of organism and/or preventing colorectal adenoma; and/or (v) facilitate the production of antibodies and enhance immunity.

The carbohydrate material of the present invention may be sucrose, for example white sugar.

In a preferred embodiment of the invention, the short chain fatty acids comprise C1-C6 fatty acids.

In a preferred embodiment of the present invention, the short chain fatty acid comprises intestinal short chain fatty acid.

In a preferred embodiment of the present invention, the intestinal tract includes a small intestine and/or a large intestine.

In a preferred embodiment of the present invention, the "increase in the content of short-chain fatty acid" means to increase the content of short-chain fatty acid in a subject.

Preferably, the subject comprises a human or non-human mammal.

Health sugar and preparation method thereof

The invention also provides a healthy sugar, which comprises arabinose, arabinoxylan and sucrose.

In a preferred embodiment of the present invention, the sucrose comprises white granulated sugar.

In a preferred embodiment of the present invention, the healthy sugar comprises a characteristic selected from the group consisting of:

In a preferred embodiment of the present invention, the weight ratio of arabinose, arabinoxylan and sucrose is (1-90): (1-50): (1-50).

In a preferred embodiment of the invention, the preparation of the healthy sugar is an oral preparation.

The invention also provides a preparation method of the healthy sugar, which comprises the following steps:

In a preferred embodiment of the present invention, in the step (1), the particle size distribution of the pulverized sucrose is as follows: d10-86-90 μm, D50-150-156 μm, and D90-253-260 μm.

In a preferred embodiment of the present invention, in the step (2), the particle size distribution of the crushed arabinose is as follows: d10-65-70 μm, D50-120-125 μm, D90-210-215 μm;

in a preferred embodiment of the present invention, in the step (3), the particle size distribution of the pulverized arabinoxylan is as follows: d10-40-45 μm, D50-77-83 μm, and D90-130-135 μm.

In a preferred embodiment of the present invention, in the step (4), the mixing includes stirring and mixing in a mixing and stirring tank with stirring at the bottom center.

Preferably, in the step (4), the mixing includes the steps of:

In a preferred embodiment of the invention, the healthy sugar prepared by the method has a content uniformity RSD between batches and in batches of less than 2%.

The main advantages of the invention include

1. The invention discovers that the arabinose and the arabinoxylan have excellent synergistic effect on reducing the blood sugar rise caused by oral saccharide substances, thereby reducing the occurrence probability of hyperglycemia and related diseases.

2. The invention provides a healthy sugar comprising arabinose, arabinoxylan and sucrose, wherein after the healthy sugar is taken orally, the arabinose and the arabinoxylan can synergistically reduce the rise of blood sugar caused by the oral administration of the sucrose, so that the healthy sugar not only can meet the favor of high-sugar diet, but also can reduce the occurrence probability of hyperglycemia and related diseases, thereby improving the quality of life health.

3. The invention provides a preparation method of healthy sugar containing arabinose, arabinoxylan and sucrose, wherein the arabinose, the arabinoxylan and the sucrose in the healthy sugar prepared by the method have excellent content uniformity, and the arabinose, the arabinoxylan and the sucrose still have excellent content uniformity in the daily use processes of transportation, handling and the like, so that the arabinose and the arabinoxylan can keep stable content ratio in the whole use process of the healthy sugar, and further the arabinose and the arabinoxylan can play a stable blood sugar reducing effect in the whole eating process of the healthy sugar, and the application value of the healthy sugar containing the arabinose and the arabinoxylan can be improved.

The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

Example 1 examination of GI value determination for different saccharides

1. Determination of GI values for different sugars

1.1 reference standard: the test method is based on WS/T652-2019 food glycemic index determination method.

Selecting healthy adult volunteers of 12 persons, 6 men and 6 women, and the age is 20-35 years old; all the volunteers involved had a Body Mass Index (BMI) of 18.5kg/m²-24kg/m²To (c) to (d); eating rules, no history of diabetes or impaired glucose tolerance, no other metabolic diseases, digestive system diseases, endocrine system diseases, psychosis and the like; no allergic history or intolerance history of the food to be tested; nutrient supplements affecting glucose tolerance, and drugs such as oral contraceptives, acetylsalicylic acid, steroids, protease inhibitors and antipsychotics are not taken within nearly 3 months; can tolerate a fasting state of at least 10 h.

1.2 test sugars

Reference sugar: 50g of white granulated sugar.

Mixed sugar 1: mixing 50g white sugar and 4g L-arabinose.

Mixed sugar 2: mixing white sugar 50g and arabinoxylan 8 g.

Mixed sugar 3: 50g of white granulated sugar, 2g L-arabinose and 4g of arabinoxylan.

Mixed sugar 4: 50g of white granulated sugar, 3g L-arabinose and 2g of arabinoxylan.

The sugar is dissolved in purified water to 250ml, and is orally administered on the same day.

1.3 GI value determination:

GI test adopts random design, and regular work and rest and normal diet of the testee are measured in the first 3 days; determining that the dinner avoids high dietary fiber and high sugar food the day before, and starting to fast 22: 00; the test day morning was taken to avoid strenuous exercise and the subjects were sedentary for 10min before starting the test feeding. 2 fasting blood samples were collected at 5min intervals. When the food is started, the food taking time is strictly controlled, all the test objects and water are taken within 5-10min, and the time is counted from the first time of taking food. Blood samples were collected 15min, 30min, 45min, 60min, 90min and 120min, 150min after meals. The consistency and the accuracy of the blood sampling time point are ensured.

And (3) blood sugar determination: blood glucose was measured immediately after blood collection. Blood glucose concentration (ct) was measured at each time point using the glucose oxidase method according to the clinical test protocol, and each blood sample was expressed as the arithmetic mean of three independent measurements obtained under repetitive conditions in millimoles per liter (mmol/L).

And (3) drawing a blood glucose response curve: a line graph is drawn with time (t) as the abscissa and blood glucose concentration (ct) as the ordinate.

Calculating the GI value: the mean blood glucose concentration of 3 fasting blood samples in the test feeding assay was used as the fasting blood glucose base (C0).

The blood glucose change value (delta Ct) at a certain time point after meal is calculated according to the following formula:

ΔCt＝Ct-C0

in the formula: Δ Ct-postprandial blood glucose Change value in millimoles per liter (mmol/L);

ct-blood glucose concentration at a time point in millimoles per liter (mmol/L);

c0-fasting plasma glucose base in millimoles per liter (mmol/L).

The area under the blood glucose response curve increases:

the increase in area under the blood glucose response curve was calculated in millimoles per minute per liter (mmol min/L) as follows.

The method for calculating the area amplification under the blood sugar response curve comprises the following steps: the sum of the areas of the parts higher than the basal level of fasting plasma glucose was calculated geometrically based on the time (min) and the amount of change in blood glucose (mmol/L).

Calculating the GI value of the food to be detected:

in the formula: GIn-the GI value given by an individual subject;

at-the IAUC value of the food to be detected;

-average of at least 3 reference food IAUC measured for the same individual;

GI-the GI value of the food to be measured;

∑GI_n-the sum of the GI values derived from each individual subject;

n-number of subjects who eventually included in the calculation of GI value of the test food.

1.4 GI values of different test saccharides

The results of determining the GI values of different test sugars with white granulated sugar as reference sugar are shown in table 1:

TABLE 1 measurement of GI value (M. + -. SD) of various test saccharides

Group of	Measurement result of GI value
		Mixed sugar 1	66.8±3.6
Mixed sugar 2	75.9±2.9
		Mixed sugar 3	52.2±2.1
Mixed sugar 4	70.12±3.2

GI calculation, GI_{Mixed sugar}＝At_{Mixed sugar}/A_{ref (white granulated sugar)}X 100, wherein, At_{Mixed sugar}Area under the curve of the glycemic response for mixed sugars (mmol. min/L), A_{ref (white granulated sugar)}The area under the curve (mmol. min/L) of the response to blood sugar of the reference sugar white sugar.

As can be seen from table 1, the L-arabinose and arabinoxylan can effectively reduce the GI value of white granulated sugar, thereby reducing the blood sugar rise of oral white granulated sugar, reducing the blood sugar higher due to the eating of white granulated sugar and the disease occurrence probability due to the blood sugar higher, meeting the requirements of diabetes patients and people with high blood sugar, and being a healthy sugar. And from the GI values of the mixed sugars 1-3, it can be seen that L-arabinose and arabinoxylan were able to synergistically lower blood glucose levels.

Example 2 examination of the Effect of Mixed sugars on physiological metabolism in rats

1. Experimental methods

SPF-grade rats are randomly divided into a blank control group, an experimental group 1, an experimental group 2, an experimental group 3 and an experimental group 4, 10 rats in each group are freely fed for 60 days, and the rats in each group are subjected to intragastric administration once a day as follows:

blank control group: physiological saline;

experimental group 1: 0.4g/kg.bw of L-arabinose;

experimental group 2: 0.8g/kg.bw of arabinoxylan;

experimental group 3: 0.2g/kg.bw of L-arabinose and 0.4g/kg.bw of arabinoxylan;

experimental group 4: 0.3g/kg.bw of L-arabinose and 0.2g/kg.bw of arabinoxylan;

the drugs of the rats of experimental groups 1-4 were administered by gavage with physiological saline equal to that of the blank control group.

After 60 days, the feces were taken out to determine the short-chain fatty acid content of each group of rats.

2. Results of the experiment

After 60 days, the contents of short-chain fatty acids in the feces of the rats in each group are shown in Table 2 below.

TABLE 2 fecal contents of short-chain fatty acids in the rats of each group

Note: p < 0.05, ", P < 0.01 was compared to the blank control group.

As can be seen from Table 2, L-arabinose and arabinoxylan were effective in increasing the content of intestinal short-chain fatty acids (e.g., acetic acid, propionic acid and butyric acid), and from the data of experimental groups 1 to 3, L-arabinose and arabinoxylan had a synergistic effect in increasing intestinal short-chain fatty acids (e.g., acetic acid, propionic acid and butyric acid). Short chain fatty acids have a beneficial effect on the regulation of the intestinal environment, for example butyric acid is an important immunoregulatory molecule in the intestine, and it plays an important protective role in intestinal homeostasis of adaptive and innate immunity. Microbial deregulation alters the formation of Short Chain Fatty Acids (SCFAs), such as acetate, propionate and butyrate, which are used by colonic cells as an important energy source, which inhibit fat synthesis by the liver and thus function to reduce weight. The short-chain fatty acid is a main energy source of intestinal epithelial cells, and can maintain the acid-base balance of intestinal tracts and inhibit the survival of harmful bacteria. The short-chain fatty acid can also improve immune cell factors of human bodies and promote the immune response of hosts; meanwhile, the appetite of people can be influenced through the reaction of the brain and intestinal axis to adjust the energy balance, so that the weight-losing tea has an inhibiting effect on obesity and metabolic diseases. Diet is one of the major factors affecting the composition of the gut microbiota, since food exerts selective pressure on the gut microbiota, thereby affecting the metabolites it produces. Therefore, the L-arabinose and the arabinoxylan can effectively improve the content of intestinal short-chain fatty acids (such as acetic acid, propionic acid and butyric acid), can obviously improve the intestinal environment, promotes the health of organisms and further prevents intestinal diseases such as rectal adenoma and the like.

Example 3

This example 3 provides a healthy candy and a method for producing the same.

The formula of healthy sugar is shown in table 3:

TABLE 3 prescription of healthy sugar

Components	Parts by weight
		White granulated sugar	500
L-arabinose	20
		Arabinoxylan	40

The preparation method comprises the following steps:

the preparation method of the health sugar comprises the following steps:

(1) white sugar was treated as follows:

crushing 500 parts by weight of white granulated sugar to obtain crushed white granulated sugar, wherein the particle size distribution of the crushed white granulated sugar is as follows: d10 ═ 88.9 μm, D50 ═ 153.3 μm, and D90 ═ 257.8 μm.

(2) L-arabinose was treated as follows:

crushing 20 parts by weight of L-arabinose to obtain crushed L-arabinose, wherein the particle size distribution of the crushed L-arabinose is as follows: d10 ═ 67.6 μm, D50 ═ 122.1 μm, and D90 ═ 213.8 μm.

(3) Arabinoxylan was treated as follows:

pulverizing 40 parts by weight of arabinoxylan to obtain pulverized arabinoxylan, wherein the particle size distribution of the pulverized arabinoxylan is as follows: d10 ═ 43.5 μm, D50 ═ 79.8 μm, and D90 ═ 133.2 μm.

(4) Stirring and mixing the crushed white granulated sugar in the step (1), the crushed L-arabinose in the step (2) and the crushed arabinoxylan in the step (3) in a mixing and stirring tank with a stirring effect at the center of the bottom, wherein the mixing method comprises the following steps:

stirring 1/5 amount of crushed white granulated sugar, 1/4 amount of crushed L-arabinose and 1/3 amount of crushed arabinoxylan for 8min at 120 r/min, then adding 3/5 amount of crushed white granulated sugar, 2/4 amount of crushed L-arabinose and 1/3 amount of crushed arabinoxylan, stirring for 10min at 200 r/min, finally adding the rest 1/5 amount of crushed white granulated sugar, the rest 1/4 amount of crushed L-arabinose and the rest 1/3 amount of crushed arabinoxylan, and stirring for 15min at 320 r/min to obtain the health sugar.

The healthy candy prepared by the embodiment has fine and smooth mouthfeel, quick melting in mouth and good mouthfeel.

And (3) measuring the mixing uniformity:

measuring the content of L-arabinose in the healthy sugar by High Performance Liquid Chromatography (HPLC), wherein the HPLC chromatographic conditions are as follows:

an Agilent high performance liquid chromatograph;

a chromatographic column: lead-type sugar column (CHO 682, 7.8mm × 300mm, 7 μm);

mobile phase: pure water;

flow rate: 0.4ml/min

Sample introduction volume: 20 μ l

Column temperature: 80 ℃;

a detector: a difference detector.

3 batches of healthy sugars were prepared in parallel, and 7 samples (for 21 parts) were taken from the upper, middle and lower parts of each batch of healthy sugars, respectively, and the L-arabinose content (wt%) in the 21 samples of each batch was measured by HPLC as shown in Table 4 below:

TABLE 4L-arabinose content in 21 samples of each batch

As can be seen from Table 4, the healthy sugars prepared in this example have excellent content uniformity (RSD < 2%) both between and within batches.

Study of stability in use

Packing 3 batches of healthy sugar bags prepared in parallel, putting the bags into a workbench of a BenchWaver wavy table (3D), setting the rotating speed of the BenchWaver wavy table (3D) to be 30rpm, and setting the inclination angle of the workbench: and 3D wave-type shaking oscillation is carried out for 2 hours at 10 degrees, and the processes of daily transportation, taking and placing of the bags filled with the healthy sugar and the like are simulated.

After the shaking was completed, 7 samples (for 21 portions) were taken from the upper, middle and lower portions of the sub-bag containing healthy sugar by using a sampler, and the L-arabinose content (wt%) in the 21 samples of each lot was measured by HPLC as shown in the following Table 5:

TABLE 5L-arabinose content in 21 samples of each batch

As can be seen from Table 5, the prepared healthy sugar maintained excellent content uniformity (RSD < 5%) both between and within batches, even during long-term three-dimensional wave-like shaking. Therefore, the prepared healthy sugar can keep excellent mixing uniformity in the processes of daily transportation, handling and the like.

Comparative example 1

This comparative example provides a healthy candy, which is formulated and prepared in the same manner as in example 3, except that:

the particle size distribution of the crushed white granulated sugar prepared in the step (1) is as follows: d10 ═ 127.5 μm, D50 ═ 247.1 μm, and D90 ═ 367.4 μm.

Study of stability in use

The healthy sugar prepared in this comparative example was measured for content uniformity after 3D wave shaking of the healthy sugar according to the "in-use stability study" method in example 3, and after the shaking was completed, 3 samples (for 9 parts) were taken from the upper, middle and lower portions of the bag containing the healthy sugar using a sampler, and the L-arabinose content (wt%) in the 9 samples of each lot was measured by HPLC as shown in Table 6 below:

TABLE 6L-arabinose content in 9 samples of each batch

As can be seen from Table 6, the content uniformity RSD of the healthy candy prepared in comparative example 1 after 3D wave shaking is more than 5%, indicating that the content uniformity of the healthy candy is poor in the processes of daily transportation, handling and the like.

While the invention has been described in terms of a preferred embodiment, it will be understood by those skilled in the art that various changes in form and detail may be made without departing from the spirit and scope of the invention.

Claims

1. A composition comprising arabinose and arabinoxylan.

2. The composition according to claim 1, wherein the weight ratio of arabinose and arabinoxylan is 1: 0.2-8, preferably 1: 1-5, more preferably 1: 1.5-3, more preferably 1: 1.5-2.5, more preferably 1: 1.8-2.2, more preferably 1: 2.

3. the composition of claim 1, wherein the composition is a pharmaceutical composition, a food composition, or a nutraceutical composition.

4. The composition of claim 1, wherein the composition is in the form of an oral formulation or an injectable formulation.

5. Use of a composition according to claim 1 for the preparation of a medicament, food or dietary supplement for: (i) preventing and/or treating elevated blood glucose caused by oral administration of a saccharide; (ii) reducing the blood glucose rise caused by oral administration of carbohydrates; (iii) the content of short-chain fatty acid is increased; (iv) improving intestinal environment, promoting health of organism and/or preventing colorectal adenoma; and/or (v) facilitate the production of antibodies and enhance immunity.

6. The use of claim 5, wherein the carbohydrate material comprises sucrose; and/or

The short chain fatty acid comprises one or more of acetic acid, propionic acid and butyric acid.

7. A healthy sugar that lowers the Glycemic Index (GI) comprising arabinose, arabinoxylan, and sucrose.

8. The healthy sugar of claim 7, wherein the weight ratio of sucrose, arabinose and arabinoxylan is 0.5 to 99: 0.5-99: 0.5-99.

9. A method for preparing the healthy sugar according to claim 7, comprising the steps of:

10. The method of claim 9, wherein in step (1), the particle size distribution of the milled sucrose is as follows: d10-86-90 μm, D50-150-260 μm, D90-253-156 μm;

in the step (2), the particle size distribution of the crushed arabinose is as follows: d10-65-70 μm, D50-120-125 μm, D90-210-215 μm; and/or